Document is current
Any future updates will be listed below
-
Authors
Musher, Benjamin L. https://orcid.org/0000-0002-4997-1751
Vasileiou, Spyridoula https://orcid.org/0000-0002-7970-9391
Smaglo, Brandon G. https://orcid.org/0000-0002-8814-8004
Robertson, Catherine S.
Wu, Mengfen
Wang, Tao https://orcid.org/0000-0003-1957-7160
Watanabe, Ayumi
Kuvalekar, Manik
Velazquez, Yovana
Ketkar, Shamika
Doheyan, Tamadar Al https://orcid.org/0000-0002-6425-6676
Papayanni, Penelope G.
Shah, Aakash
Lapteva, Natalia
Grilley, Bambi J.
Van Buren, George https://orcid.org/0000-0001-7637-3717
Lulla, Premal D.
Heslop, Helen E. https://orcid.org/0000-0001-7049-7698
Rooney, Cliona M.
Brenner, Malcolm K.
Leen, Ann M. https://orcid.org/0000-0002-4470-1760
- License Information
-
More Information
Article History
Received: 16 May 2025
Accepted: 30 September 2025
First Online: 2 January 2026
Competing interests
: B.L.M. receives research funding from Diakonos and LOKON and has a consulting agreement with Gnubiotics. B.J.G. owns QBRegulatory Consulting, which has consulting agreements with Tessa Therapeutics, Marker Therapeutics, LOKON and AlloVir. H.E.H. is a co-founder with equity in AlloVir and Marker Therapeutics, has served on advisory boards for Tessa Therapeutics, Kiadis, Novartis, Gilead Biosciences, Fresh Wind Biotechnologies and GSK, has share options in March Biosciences and CoRegen and received research support from Kuur Therapeutics and Tessa Therapeutics. C.M.R. and M.K.B. have stock and other ownership interests with Coya, Bluebird Bio, Tessa Therapeutics, Marker Therapeutics, AlloVir, Walking Fish, Allogene Therapeutics, Memgen, Kuur Therapeutics, Bellicum Pharmaceuticals, TScan Therapeutics, Abintus Bio and March Biosciences, consulting or advisory roles with Abintus Bio, Adaptimmune, Brooklyn Immunotherapeutic, Onk Therapeutics, Tessa Therapeutics, Memgen, Torque, Walking Fish Therapeutics, TScan Therapeutics, Marker Therapeutics and Turnstone Bio and receive research funding from Kuur Therapeutics. A.M.L. is a co-founder and equity holder for AlloVir and Marker Therapeutics and was a consultant to AlloVir. S.V. and M.K. were consultants to AlloVir. B.G.S. receives research funding from Merck and AstraZeneca and has a consulting agreement with Boehringer Ingelheim. The remaining authors declare no competing interests.
